Stay updated about genetic testing and targeted treatments for BRCA mutations in prostate cancer

Janssen is committed to researching targeted treatment approaches to help patients with the most aggressive forms of prostate cancer, including men with BRCA mutations.

Janssen Biotech, Inc., our affiliates, and our service providers will use the information that you provide to send you communications about Janssen, prostate cancer and your optional requests, and to research, develop, and improve our products and services. You may unsubscribe from these communications by following the instructions in them. Our Privacy Policy further governs the use of the information you provide.